These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 24143237)
21. 5-(2-18F-fluoroethoxy)-L-tryptophan as a substrate of system L transport for tumor imaging by PET. Krämer SD; Mu L; Müller A; Keller C; Kuznetsova OF; Schweinsberg C; Franck D; Müller C; Ross TL; Schibli R; Ametamey SM J Nucl Med; 2012 Mar; 53(3):434-42. PubMed ID: 22331220 [TBL] [Abstract][Full Text] [Related]
22. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. Holland JP; Divilov V; Bander NH; Smith-Jones PM; Larson SM; Lewis JS J Nucl Med; 2010 Aug; 51(8):1293-300. PubMed ID: 20660376 [TBL] [Abstract][Full Text] [Related]
23. Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET. Ruggiero A; Holland JP; Hudolin T; Shenker L; Koulova A; Bander NH; Lewis JS; Grimm J J Nucl Med; 2011 Oct; 52(10):1608-15. PubMed ID: 21908391 [TBL] [Abstract][Full Text] [Related]
24. Synthesis and evaluation of 2-amino-5-(4-[(18)F]fluorophenyl)pent-4-ynoic acid ([(18)F]FPhPA): a novel (18)F-labeled amino acid for oncologic PET imaging. Way JD; Wang M; Hamann I; Wuest M; Wuest F Nucl Med Biol; 2014 Sep; 41(8):660-9. PubMed ID: 24993371 [TBL] [Abstract][Full Text] [Related]
25. Production and characterization of highly tumor-specific rat monoclonal antibodies recognizing the extracellular domain of human L-type amino-acid transporter 1. Ohno Y; Suda K; Masuko K; Yagi H; Hashimoto Y; Masuko T Cancer Sci; 2008 May; 99(5):1000-7. PubMed ID: 18294274 [TBL] [Abstract][Full Text] [Related]
26. Glioblastoma Exhibits Inter-Individual Heterogeneity of TSPO and LAT1 Expression in Neoplastic and Parenchymal Cells. Cai L; Kirchleitner SV; Zhao D; Li M; Tonn JC; Glass R; Kälin RE Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963507 [TBL] [Abstract][Full Text] [Related]
27. Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab. Jagoda EM; Lang L; Bhadrasetty V; Histed S; Williams M; Kramer-Marek G; Mena E; Rosenblum L; Marik J; Tinianow JN; Merchant M; Szajek L; Paik C; Cecchi F; Raffensperger K; Jose-Dizon JM; Bottaro DP; Choyke P J Nucl Med; 2012 Oct; 53(10):1592-600. PubMed ID: 22917884 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of (89)Zr-labeled human anti-CD147 monoclonal antibody as a positron emission tomography probe in a mouse model of pancreatic cancer. Sugyo A; Tsuji AB; Sudo H; Nagatsu K; Koizumi M; Ukai Y; Kurosawa G; Zhang MR; Kurosawa Y; Saga T PLoS One; 2013; 8(4):e61230. PubMed ID: 23577210 [TBL] [Abstract][Full Text] [Related]
29. Preclinical characterization of 18F-D-FPHCys, a new amino acid-based PET tracer. Denoyer D; Kirby L; Waldeck K; Roselt P; Neels OC; Bourdier T; Shepherd R; Katsifis A; Hicks RJ Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):703-12. PubMed ID: 22160176 [TBL] [Abstract][Full Text] [Related]
30. The role of LAT1 in (18)F-DOPA uptake in malignant gliomas. Youland RS; Kitange GJ; Peterson TE; Pafundi DH; Ramiscal JA; Pokorny JL; Giannini C; Laack NN; Parney IF; Lowe VJ; Brinkmann DH; Sarkaria JN J Neurooncol; 2013 Jan; 111(1):11-8. PubMed ID: 23086431 [TBL] [Abstract][Full Text] [Related]
31. ImmunoPET imaging of tissue factor expression in pancreatic cancer with Hernandez R; England CG; Yang Y; Valdovinos HF; Liu B; Wong HC; Barnhart TE; Cai W J Control Release; 2017 Oct; 264():160-168. PubMed ID: 28843831 [TBL] [Abstract][Full Text] [Related]
32. Biodistribution and PET Imaging of Labeled Bispecific T Cell-Engaging Antibody Targeting EpCAM. Warnders FJ; Waaijer SJ; Pool M; Lub-de Hooge MN; Friedrich M; Terwisscha van Scheltinga AG; Deegen P; Stienen SK; Pieslor PC; Cheung HK; Kosterink JG; de Vries EG J Nucl Med; 2016 May; 57(5):812-7. PubMed ID: 26848172 [TBL] [Abstract][Full Text] [Related]
37. ImmunoPET Imaging of Insulin-Like Growth Factor 1 Receptor in a Subcutaneous Mouse Model of Pancreatic Cancer. England CG; Kamkaew A; Im HJ; Valdovinos HF; Sun H; Hernandez R; Cho SY; Dunphy EJ; Lee DS; Barnhart TE; Cai W Mol Pharm; 2016 Jun; 13(6):1958-66. PubMed ID: 27054683 [TBL] [Abstract][Full Text] [Related]
38. What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between Bailly C; Gouard S; Guérard F; Chalopin B; Carlier T; Faivre-Chauvet A; Remaud-Le Saëc P; Bourgeois M; Chouin N; Rbah-Vidal L; Tripier R; Haddad F; Kraeber-Bodéré F; Bodet-Milin C; Chérel M Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137758 [TBL] [Abstract][Full Text] [Related]
39. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing Cho H; Al-Saden N; Lam H; Möbus J; Reilly RM; Winnik MA Nucl Med Biol; 2020; 84-85():11-19. PubMed ID: 31931305 [TBL] [Abstract][Full Text] [Related]
40. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Perk LR; Stigter-van Walsum M; Visser GW; Kloet RW; Vosjan MJ; Leemans CR; Giaccone G; Albano R; Comoglio PM; van Dongen GA Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1857-67. PubMed ID: 18491091 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]